Cobolimab with dostarlimab and docetaxel for advanced non-small-cell lung cancer after anti-PD-L1 therapy and chemotherapy

Cobolimab in combination with dostarlimab and docetaxel is in clinical development for the treatment of advanced non-small cell lung cancer (NSCLC) in patients who have progressed on prior treatment with anti-PD-L1 therapy and chemotherapy. NSCLC is the most common type of lung cancer. Symptoms include a cough, repeated chest infections, breathlessness, unexplained pain, weight loss or tiredness. Cobolimab and dostarlimab combined has the potential to improve anti-tumour immunity.